2016 Volume 5 Issue 2 Pages 27-34
Because of their immunosuppressive abilities, mesenchymal stromal cells (MSCs) have been employed in clinical studies to treat steroid-refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation. A number of studies have suggested that MSC infusion is safe and might be effective for treating acute GVHD. However, well-designed comparative studies are required to more precisely assess the impact of MSC infusion on GVHD treatment. Because MSCs form a bone marrow micro-environment and support hematopoiesis, they have been employed in clinical studies to facilitate hematopoietic recovery after cord blood transplantation and HLA-haploidentical donor transplantation. Some studies have demonstrated high engraftment rate and rapid neutrophil recovery. However, information is scarce. Further studies are required.
